Biotech Breakout?
Executive Summary
1990 Value.... 722.1 1991 Value.... 1814.7 1992 Value.... 1586.7 1993 Value.... 1385.5 1994 Value.... 877.9 1995 Value.... 1529.2 1996 Value.... 1355.6 1997 Value.... 1377.5 1998 Value.... 2173.7 1999 Value.... 4313.1
You may also be interested in...
Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Colfax Plans To Split To Form Separate Medtech And Fabtech Companies
The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.
What Does A Typical Refuse-To-File Letter Look Like?
Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: